Singapore markets close in 47 minutes

60 Degrees Pharmaceuticals, Inc. (SXTP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2750+0.0099 (+3.73%)
At close: 04:00PM EDT
0.2610 -0.01 (-5.09%)
After hours: 06:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.2651
Open0.2763
Bid0.0000 x 0
Ask0.2786 x 100
Day's range0.2602 - 0.2841
52-week range0.2010 - 8.6500
Volume479,999
Avg. volume334,153
Market cap3.339M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.30
  • GlobeNewswire

    60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

    Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infectionsProminent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptomsPlanned study at North Carolina State College of Veterinary Medicine will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue/neurologic symptoms by PCRCDC estimates CFS affects 3.3 million Americans WASHINGT

  • GlobeNewswire

    60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

    Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand.Gross profit increased from ($55.9 thousand) to $51.0 thousand. WASHINGTON, May 15, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024. Financial Highlights for the Quarter Ended Marc

  • GlobeNewswire

    60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

    The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness.The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study to date.Enrollment is planned to begin in summer 2024.The Journal of Infectious Diseases has published a letter outlining the planned trial protocol. WASHINGTON, May 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NA